(NP (NP (NN Inhibition)) (PP (IN of) (NP (ADJP (JJ anti-CD3) (JJ monoclonal) (JJ antibody-induced)) (NN T-cell) (NN proliferation))) (PP (IN by) (NP (NP-COOD (NP (NN dexamethasone)) (, ,) (NP (NN isoproterenol)) (, ,) (CC or) (NP (NN prostaglandin) (NN E2))) (UCP-COOD (CC either) (ADVP (RB alone)) (CC or) (PP (IN in) (NP (NN combination)))))) (. .))
(S (LST (LS 1) (. .)) (NP-SBJ (NP (DT The) (NN purpose)) (PP (IN of) (NP (DT these) (NNS studies)))) (VP (VBD was) (S-PRD (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB investigate) (NP (NP (DT the) (NN modulation)) (PP (IN of) (NP (NP (DT the) (NN proliferation)) (PP (IN of) (NP (NP (JJ human) (NN T) (NNS cells)) (VP (VBN obtained) (NP (-NONE- *)) (PP (IN from) (NP (JJ peripheral) (NN blood)))))))) (PP (IN by) (NP-COOD (NP (NP (NN dexamethasone)) (PRN (-LRB- -LRB-) (NP (NN DEX)) (-RRB- -RRB-))) (, ,) (NP (NP (NN isoproterenol)) (PRN (-LRB- -LRB-) (NP (NN ISO)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN prostaglandin) (NN E2)) (PRN (-LRB- -LRB-) (NP (NN PGE2)) (-RRB- -RRB-)))))))))) (. .))
(S (NP-SBJ (DT The) (JJ former) (CD two) (NNS substances)) (VP (VBP interact) (PP (IN with) (NP (NN T) (NNS cells))) (PP (IN via) (NP (DT the) (UCP-COOD (NP (NN glucocorticoid)) (CC and) (ADJP (JJ beta-adrenergic))) (NNS receptors))) (ADVP (RB respectively))) (. .))
(S (SBAR-TMP (WHADVP-11 (WRB When)) (S (NP-SBJ-13 (-NONE- *-12)) (VP (VBN occupied) (NP-14 (-NONE- *-13)) (PP (IN by) (NP-LGS (NP (PRP$ their) (JJ natural) (NNS ligands)) (, ,) (NP-COOD (NP (NNS glucocorticosteroids)) (CC and) (NP (NNS catecholamines)))) (ADVP (-NONE- *T*-11)))))) (, ,) (NP-SBJ-12 (DT these) (NNS receptors)) (VP (VBP have) (NP (DT a) (NN role)) (PP (IN in) (S (NP-SBJ (-NONE- *-14)) (VP (VBG modulating) (NP (NN T-cell) (NN function)) (PP-TMP (IN during) (NP (NN stress))))))) (. .))
(S (PP-TMP (IN During) (NP (DT the) (JJ inflammatory) (NN response))) (NP-SBJ (NP (VBN increased) (NNS levels)) (PP (IN of) (NP (NN PGE2)))) (VP-COOD (VP (VBP bind) (PP (TO to) (NP (NP (PRP$ their) (NNS receptors)) (PP (IN on) (NP (NN T) (NNS cells)))))) (CC and) (RB thus) (VP (VBP alter) (NP (NN responsiveness)))) (. .))
(S (NP-SBJ-15 (NP (NN Proliferation)) (PP (IN of) (NP (NN T) (NNS cells)))) (VP (VBD was) (VP (VBN induced) (NP (-NONE- *-15)) (PP (IN by) (NP-LGS (VBN immobilized) (JJ anti-CD3) (NP (NP (JJ monoclonal) (NN antibody)) (PRN (-LRB- -LRB-) (NP (NN mAb)) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (DT the) (NP-COOD (NP (NN presence)) (CC or) (NP (NN absence)))) (PP (IN of) (NP (NP (DT an) (JJ additional) (JJ costimulatory) (NN signal)) (VP (VBN delivered) (NP (-NONE- *)) (PP (IN by) (NP-LGS (JJ anti-CD28) (NN mAb)))))))))) (. .))
(S (LST (LS 2) (. .)) (S-COOD (S (NP-SBJ-16 (NP (JJ Various) (JJ physiologic) (NNS concentrations)) (PP (IN of) (NP-COOD (NP (NN DEX)) (, ,) (NP (NN ISO)) (, ,) (CC or) (NP (NN PGE2))))) (VP (VBD were) (VP (VBN added) (NP (-NONE- *-16)) (PP-TMP (IN at) (NP (NP (DT the) (NN time)) (PP (IN of) (NP (NP (NN initiation)) (PP (IN of) (NP (DT the) (NNS cultures)))))))))) (CC and) (S (NP-SBJ-17 (NP (JJ subsequent) (NN proliferation)) (PP (IN of) (NP (DT the) (JJ unstimulated) (NN T) (NNS cells)))) (VP (VBD was) (VP (VBN determined) (NP (-NONE- *-17)))))) (. .))
(S (NP-SBJ (DT The) (NNS results)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ (NP (JJ physiologic) (NNS concentrations)) (PP (IN of) (NP (NP (DT all) (CD three)) (PP (IN of) (NP (DT these) (NNS agents)))))) (VP (VBP inhibit) (NP (NP (DT the) (ADJP (JJ anti-CD3) (JJ mAb-induced)) (NN proliferation)) (PP (IN of) (NP (NN T) (NNS cells)))))))) (. .))
(S (LST (LS 3) (. .)) (SBAR-ADV (IN Although) (S (NP-SBJ-COOD-18 (NP (NN DEX)) (CC and) (NP (NN PGE2))) (VP (VBD were) (ADJP-PRD (JJ equipotent)) (PP (IN in) (S (NP-SBJ (-NONE- *-18)) (VP (JJ suppressing) (NP (NN T-cell) (NN proliferation)))))))) (, ,) (NP-SBJ (NN ISO)) (VP (VBD was) (ADJP-PRD (ADVP (RB much) (RBR less)) (JJ effective))) (. .))
(S (LST (LS 4) (. .)) (SBAR-ADV (IN Because) (S (NP-SBJ (NP (JJ concomitant) (NNS elevations)) (PP (IN in) (NP (NP (DT the) (JJ peripheral) (NNS levels)) (PP (IN of) (NP (DT these) (NNS substances)))))) (VP (MD may) (VP (VB occur))))) (, ,) (NP-SBJ-19 (NNS experiments)) (VP (VBD were) (VP (VBN performed) (NP (-NONE- *-19)) (S (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN T-cell) (JJ inhibitory) (NNS effects)) (PP (IN of) (NP (NN DEX))) (PP (RB together) (IN with) (NP-COOD (CC either) (NP (NN PGE2)) (CC or) (NP (NN ISO)))))))))) (. .))
(S (NP-SBJ-20 (NP (JJ Synergistic) (NN suppression)) (PP (IN of) (NP (NN T-cell) (NN proliferation)))) (VP (VBD was) (VP (VBN observed) (NP (-NONE- *-20)) (SBAR-TMP (WHADVP-21 (WRB when)) (S (NP-SBJ-22 (NP (JJ various) (NNS concentrations)) (PP (IN of) (NP-COOD (NP-COOD (NP (NN DEX)) (CC and) (NP (NN PGE2))) (, ,) (CONJP (CC but) (RB not)) (NP-COOD (NP (NN DEX)) (CC and) (NP (NN ISO))) (, ,)))) (VP (VBD were) (VP (VBN added) (NP (-NONE- *-22)) (PP (TO to) (NP (NNS cultures))) (ADVP (-NONE- *T*-21)))))))) (. .))
(S (NP-SBJ-23 (DT This) (JJ synergistic) (NN suppression)) (VP (MD could) (RB not) (VP (VB be) (VP (VBN explained) (NP (-NONE- *-23)) (PP (IN by) (NP-LGS (NP (DT an) (NN increase)) (PP (IN in) (NP (NP (NN cAMP) (NN accumulation)) (PP (IN in) (NP (NP (NN T) (NNS cells)) (VP (VBN stimulated) (NP (-NONE- *)) (PP (IN with) (NP-COOD (NP (NN DEX)) (CC and) (NP (NN PGE2)))))))))))))) (. .))
(S (LST (LS 5) (. .)) (ADVP (RB Finally)) (, ,) (NP-SBJ (NP (DT the) (NN addition)) (PP (IN of) (NP (JJ anti-CD28) (NN mAb))) (PP (TO to) (NP (ADJP (JJ anti-CD3) (JJ mAb-stimulated)) (NN T) (NNS cells)))) (VP (VBD overcame) (NP (NP (JJ much)) (PP (IN of) (NP (NP (DT the) (NN suppression)) (PP (IN of) (NP (NN proliferation))) (VP (VBN induced) (NP (-NONE- *)) (PP (IN by) (NP-LGS-COOD (NP (NN PGE2)) (CC or) (NP (NN ISO)))))))) (CC but) (ADVP (ADVP (RBR less) (RB so)) (PP (IN than) (NP (NP (DT that)) (VP (VBN induced) (NP (-NONE- *)) (PP (IN by) (NP-LGS (NN DEX)))))))) (. .))
